Wagner Wealth Management LLC Reduces Stock Position in Johnson & Johnson (NYSE:JNJ)

Wagner Wealth Management LLC trimmed its position in Johnson & Johnson (NYSE:JNJ) by 10.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,924 shares of the company’s stock after selling 438 shares during the quarter. Wagner Wealth Management LLC’s holdings in Johnson & Johnson were worth $568,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of JNJ. IFS Advisors LLC lifted its holdings in shares of Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after buying an additional 100 shares during the period. Highline Wealth Partners LLC purchased a new position in Johnson & Johnson during the third quarter valued at approximately $31,000. Bay Harbor Wealth Management LLC purchased a new stake in Johnson & Johnson in the 4th quarter worth approximately $32,000. RPg Family Wealth Advisory LLC acquired a new stake in shares of Johnson & Johnson during the 3rd quarter worth approximately $35,000. Finally, Mowery & Schoenfeld Wealth Management LLC lifted its stake in shares of Johnson & Johnson by 58.7% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after purchasing an additional 91 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling

In other news, Director Mark A. Weinberger purchased 1,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 0.16% of the stock is owned by company insiders.

Analysts Set New Price Targets

JNJ has been the subject of a number of recent analyst reports. Guggenheim lifted their price objective on shares of Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a report on Monday, February 3rd. Stifel Nicolaus reduced their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a report on Thursday, January 23rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 16th. Raymond James reduced their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Finally, Wells Fargo & Company dropped their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $170.67.

Johnson & Johnson Stock Down 0.6 %

JNJ stock opened at $155.23 on Thursday. The company has a market cap of $373.73 billion, a price-to-earnings ratio of 23.34, a PEG ratio of 2.46 and a beta of 0.52. The firm has a 50-day moving average of $147.48 and a two-hundred day moving average of $156.01. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The firm’s revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.29 earnings per share. As a group, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.20%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.